What Makes Vir Biotechnology (VIR) a New Buy Stock
Yahoo FinanceApr 24 12:00 ET
Vir Biotechnology Announces CFO Departure and Board Expansion
TipRanksApr 18 09:02 ET
Express News | Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.d. and Ramy Farid, Ph.d. to Its Board of Directors
Moomoo 24/7Apr 18 08:00 ET
Express News | Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Moomoo 24/7Apr 11 16:30 ET
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution
In the last year, many Vir Biotechnology, Inc. (NASDAQ:VIR) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it i
Simply Wall StApr 8 07:49 ET
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Yahoo FinanceApr 4 19:01 ET
Form 144 | Vir Biotechnology(VIR.US) Officer Proposes to Sell 350.58K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 4, $Vir Biotechnology(VIR.US)$ Officer Pang Phillip intends to sell 37,535 shares of its common stock on Apr 4, with a total market value of approximately $350.58K. Pang
moomoo NewsApr 4 15:37 ET
Form 144 | Vir Biotechnology(VIR.US) Insider Proposes to Sell 504.59K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $Vir Biotechnology(VIR.US)$ Insider PHILLIP PANG intends to sell 53,000 shares of its common stock on Apr 3, with a total market value of approximately $504.59K. PHILL
moomoo NewsApr 3 16:19 ET
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Vir Biotechnology (NASDAQ:VIR) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments, the tab
BenzingaMar 15 10:00 ET
Express News | HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Moomoo 24/7Mar 15 09:26 ET
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
TipRanksMar 15 06:20 ET
Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning
TipRanksMar 11 00:46 ET
Express News | Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial
Moomoo 24/7Mar 5 08:06 ET
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
BusinesswireMar 5 08:05 ET
Optimistic Outlook for Vir Biotechnology's Clinical Programs and Financial Position Reinforces Buy Rating
TipRanksFeb 25 23:29 ET
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Dow JonesFeb 23 12:43 ET
Vir Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/23/2024 -13.19% JP Morgan $9 → $10 Maintains Neutral 02/14/2024 854.86% HC Wainwright & Co. $85 → $110
BenzingaFeb 23 12:32 ET
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Carvana Co. (NYSE:CVNA) rose sharply during Friday's session after the company reported four
BenzingaFeb 23 11:58 ET
Vir Biotechnology Shares Rise 14% on Terminated Collaboration With GSK
By Denny Jacob Vir Biotechnology shares rose 14% to $11.72 following a terminated collaboration with GSK regarding the flu. The stock is down about 55% over the last 12 months. The clinical-stage i
WSJFeb 23 10:57 ET
Vir Biotechnology, Community Health Systems Among Healthcare Movers
Seeking AlphaFeb 23 10:00 ET
No Data
No Data